AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18539917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (targeting glycated hemoglobin level below 6.0%)
Number of subjects: 10251
Study 18539917 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (targeting glycated hemoglobin level from 7.0 to 7.9%)
Number of subjects: 10251
Study 18539917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 10251
Study 18539917 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 10251
Study 16038713 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg plus acetylsalicylic acid 75 mg
Number of subjects: 23
Study 16038713 — intervention group
Group type: COMPARATOR
Intervention: Extended-release dipyridamole 200 mg plus acetylsalicylic acid 25 mg
Number of subjects: 23
Study 12096265 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-flow duplex (CFD) scan
Number of subjects: 79
Study 12096265 — intervention group
Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 79
Study 10090427 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading-dose metrifonate (100 mg or 150 mg for 2 weeks, then 50 mg for 4 weeks)
Number of subjects: 395
Study 10090427 — intervention group
Group type: EXPERIMENTAL
Intervention: No-loading-dose metrifonate (50 mg for 6 weeks)
Number of subjects: 395
Study 10090427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 10090427 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading-dose metrifonate
Number of subjects: 395
Study 10090427 — intervention group
Group type: EXPERIMENTAL
Intervention: No-loading-dose metrifonate
Number of subjects: 395
Study 8539322 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 12
Study 8539322 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg)
Number of subjects: 12
Study 8539322 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) and (100 mg)
Number of subjects: 12
Study 8539322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2404388 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU streptokinase
Number of subjects: 189
Study 2404388 — intervention group
Group type: EXPERIMENTAL
Intervention: 750,000 IU streptokinase
Number of subjects: 189
Study 2404388 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500,000 IU streptokinase
Number of subjects: 189
Study 2404388 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000,000 IU streptokinase
Number of subjects: 189
Study 2404388 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of streptokinase
Number of subjects: 189
Study 656266 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (n=7)
Number of subjects: 21
Study 656266 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (n=6)
Number of subjects: 21
Study 656266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 21
Study 6356901 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol alone (100 to 1,200 mg twice a day)
Number of subjects: 337
Study 6356901 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol in combination with a diuretic
Number of subjects: 337
Study 6356901 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (with or without diuretic)
Number of subjects: 337
Study 31783766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic intensity‐modulated radiation therapy (IMRT) of 50 Gy/25Fx concurrently with capecitabine and oxaliplatin (Arm A)
Number of subjects: 120
Study 31783766 — intervention group
Group type: COMPARATOR
Intervention: Pelvic radiation of 50 Gy/25Fx with a concomitant boost of 5 Gy to the primary lesion, followed by a cycle of XELOX 2 weeks after the end of CRT (Arm B)
Number of subjects: 120
Study 31783766 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 120
Study 31783766 — intervention group
Group type: COMPARATOR
Intervention: Arm B
Number of subjects: 120
Study 28859184 — intervention group
Group type: EXPERIMENTAL
Intervention: Blepharoplasty
Number of subjects: 401
Study 27039894 — intervention group
Group type: EXPERIMENTAL
Intervention: Light‐emitting diode‐mediated‐photobiomodulation therapy (LPT) applied with an energy density of 20 mW/cm2 for 21 successive days (20 minutes per day) over the movement of canine teeth.
Number of subjects: 20
Study 27039894 — intervention group
Group type: EXPERIMENTAL
Intervention: Light‐emitting diode‐mediated‐photobiomodulation therapy (LPT)
Number of subjects: 20
Study 27039894 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo application of LPT)
Number of subjects: 20
Study 24215032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) injections (1.25 mg/0.05 mL)
Number of subjects: 105
Study 22504600 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly oral periodic presumptive treatment (PPT; 2 g metronidazole + 150 mg fluconazole)
Number of subjects: 165
Study 22504600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 19422409 — intervention group
Group type: EXPERIMENTAL
Intervention: US-assisted femoral nerve block (FNB)
Number of subjects: 67
Study 19422409 — intervention group
Group type: COMPARATOR
Intervention: Fascial pop (FP) technique
Number of subjects: 67
Study 17470024 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 90
Study 17470024 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine spray
Number of subjects: 90
Study 17470024 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine spray
Number of subjects: 90
Study 15533734 — intervention group
Group type: EXPERIMENTAL
Intervention: C12 peptide with higher dose of alginic acid (1754 mg)
Number of subjects: 10
Study 11973116 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interventions (two telephone contacts in addition to treatment as usual)
Number of subjects: 216
Study 11973116 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (no telephone interventions)
Number of subjects: 216
Study 11973116 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interventions
Number of subjects: 216
Study 9717819 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/m2 9‐AC p.o. on day 1
Number of subjects: 12
Study 9717819 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/m2 9‐AC i.v. on day 8
Number of subjects: 12
Study 8127017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 50
Study 8127017 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 50
Study 8127017 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 50
Study 8127017 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 50
Study 2573371 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tertatolol
Number of subjects: 8
Study 2573371 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tertatolol with 1 g aspirin
Number of subjects: 8
Study 2573371 — intervention group
Group type: COMPARATOR
Intervention: 1 g aspirin
Number of subjects: 8
Study 2573371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3279 — intervention group
Group type: EXPERIMENTAL
Intervention: L-prolyl-Lleucyl-glycine amide (PLG)
Number of subjects: 20
Study 3279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31596213 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 85
Study 31596213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 85
Study 27986405 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h post-load plasma glucose <155 mg/dl
Number of subjects: 34
Study 27986405 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h post-load plasma glucose ≥155 mg/dl
Number of subjects: 34
Study 25705332 — intervention group
Group type: EXPERIMENTAL
Intervention: HA/DBM mixture in a PEEK cage
Number of subjects: 85
Study 25705332 — intervention group
Group type: COMPARATOR
Intervention: HA/TCP mixture in a PEEK cage
Number of subjects: 85
Study 23670707 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg/day
Number of subjects: 36
Study 23670707 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg/day
Number of subjects: 36
Study 23670707 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg/day
Number of subjects: 36
Study 23670707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21996984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (300,000 IU/month)
Number of subjects: 31
Study 21996984 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 19545297 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 2 times per week
Number of subjects: 149
Study 19545297 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 3 times per week
Number of subjects: 149
Study 19545297 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 5 times per week
Number of subjects: 149
Study 19545297 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 7 times per week
Number of subjects: 149
Study 19545297 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 149
Study 17548542 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 28
Study 17548542 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 28
Study 15570929 — intervention group
Group type: EXPERIMENTAL
Intervention: Jelco plus
Number of subjects: 40
Study 15570929 — intervention group
Group type: EXPERIMENTAL
Intervention: Insyte autoguard
Number of subjects: 40
Study 15570929 — intervention group
Group type: COMPARATOR
Intervention: All other catheters (Supercath, Introcan safety, Surshield surflo II, Safetouch cath, Protective plus, Acuvance plus)
Number of subjects: 40
Study 10817120 — intervention group
Group type: EXPERIMENTAL
Intervention: FTND score > or =8
Number of subjects: 991
Study 10817120 — intervention group
Group type: EXPERIMENTAL
Intervention: RTQ score > or =28
Number of subjects: 991
Study 10817120 — intervention group
Group type: EXPERIMENTAL
Intervention: FTND criteria
Number of subjects: 991
Study 10817120 — intervention group
Group type: EXPERIMENTAL
Intervention: RTQ criteria
Number of subjects: 991
Study 8841302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 153
Study 8841302 — intervention group
Group type: COMPARATOR
Intervention: No cryotherapy (control)
Number of subjects: 153
Study 8841302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (treated eyes)
Number of subjects: 153
Study 8841302 — intervention group
Group type: COMPARATOR
Intervention: No ROP (control group)
Number of subjects: 153
Study 1475090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml of 1% acetylcholine chloride
Number of subjects: 40
Study 1475090 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 40
Study 6397852 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed physical training
Number of subjects: 12
Study 6397852 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine 5 mg b.i.d. during double-blind, cross-over medication period
Number of subjects: 12
Study 6397852 — intervention group
Group type: COMPARATOR
Intervention: Placebo during double-blind, cross-over medication period
Number of subjects: 12
Study 6397852 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen tension measurements
Number of subjects: 12
Study 30725387 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective antimuscarinic drugs (trospium chloride, tolterodine tartrate, fesoterodine fumarate, propiverine hydrochloride)
Number of subjects: 250
Study 30725387 — intervention group
Group type: COMPARATOR
Intervention: Selective antimuscarinic drugs (darifenacin hydrobromide, solifenacin succinate, oxybutynin hydrochloride)
Number of subjects: 250
Study 30725387 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride
Number of subjects: 250
Study 30725387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine tartrate
Number of subjects: 250
Study 30725387 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine fumarate
Number of subjects: 250
Study 30725387 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine hydrochloride
Number of subjects: 250
Study 29663714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin (10-40 mg single dose; 10, 15 mg twice a day repeated doses)
Number of subjects: 0
Study 29663714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27333407 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.6 g Fortetropin supplementation
Number of subjects: 45
Study 27333407 — intervention group
Group type: EXPERIMENTAL
Intervention: 19.8 g Fortetropin supplementation
Number of subjects: 45
Study 27333407 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 45
Study 27333407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortetropin plus exercise
Number of subjects: 45
Study 27333407 — intervention group
Group type: COMPARATOR
Intervention: Control plus exercise
Number of subjects: 45
Study 25697893 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (O3FAs) - 2 capsules daily containing 180mg EPA and 120mg DHA for 3 months
Number of subjects: 478
Study 25697893 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 2 capsules of olive oil daily for 3 months
Number of subjects: 478
Study 23623487 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic adhesive drape
Number of subjects: 140
Study 23623487 — intervention group
Group type: COMPARATOR
Intervention: Bare skin
Number of subjects: 140
Study 20578379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel pricking therapy
Number of subjects: 70
Study 20578379 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (oral administration)
Number of subjects: 70
Study 19002265 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus docetaxel
Number of subjects: 102
Study 19002265 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin-based second-line therapy
Number of subjects: 102
Study 16877897 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 9
Study 16877897 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs) - fluoxetine or paroxetine (20 mg/day)
Number of subjects: 9
Study 16877897 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine in elderly patients
Number of subjects: 9
Study 14564329 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 1926
Study 10827368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 to 2.5 mg/kg)
Number of subjects: 20
Study 10827368 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study 9159196 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrosigmoidography (TC‐ESG)
Number of subjects: 24
Study 9159196 — intervention group
Group type: COMPARATOR
Intervention: Intra-sigmoid electrosigmoidography (IS‐ESG)
Number of subjects: 24
Study 1629506 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (ALB) with inhaled beclomethasone dipropionate (BDP)
Number of subjects: 111
Study 1629506 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (ALB) with oral theophylline (THEO)
Number of subjects: 111
Study 1629506 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (ALB), inhaled BDP, and oral THEO
Number of subjects: 111
Study 6333247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose mediastinal radiation
Number of subjects: 82
Study 6333247 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy and radiotherapy (without low dose mediastinal radiation)
Number of subjects: 82
Study 6333247 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (combination chemotherapy and radiotherapy)
Number of subjects: 82
Study 6333247 — intervention group
Group type: EXPERIMENTAL
Intervention: T leukaemia patients with WCC greater than 100 x 10(9)1(‐1)
Number of subjects: 82
Study 31028232 — intervention group
Group type: EXPERIMENTAL
Intervention: Model incorporating predictors of lung cancer probability
Number of subjects: 1994
Study 31028232 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model for lung cancer probability
Number of subjects: 1994
Study 30145941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin (10 mg twice daily)
Number of subjects: 12000
Study 30145941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000
Study 26829011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 2489
Study 26829011 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 2489
Study 24327173 — intervention group
Group type: EXPERIMENTAL
Intervention: Single eye-drop containing 0.0175, 0.175, or 0.7 μg rhNGF
Number of subjects: 74
Study 24327173 — intervention group
Group type: COMPARATOR
Intervention: Single ascending dose of rhNGF eye drops three times a day for 1 day (total daily dose 2.1, 6.3, or 18.9 μg)
Number of subjects: 74
Study 24327173 — intervention group
Group type: COMPARATOR
Intervention: Multiple ascending dose of rhNGF eye drops three times a day for 5 days (total dose 10.5, 31.5, or 94.5 μg)
Number of subjects: 74
Study 24327173 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 74
Study 22364387 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week exercise program including aerobic and strengthening exercises, conducted between 20 and 36 weeks of pregnancy, with one weekly group session led by physiotherapists and home exercises encouraged twice a week
Number of subjects: 855
Study 22364387 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 855
Study 20683461 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fruit program
Number of subjects: 103
Study 18363294 — intervention group
Group type: EXPERIMENTAL
Intervention: Register study
Number of subjects: 0
Study 18363294 — intervention group
Group type: COMPARATOR
Intervention: Randomized clinical trial
Number of subjects: 0
Study 15753847 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher C2 target range (1,000-1,200 ng/mL for months 4-6 and 800-1,000 ng/mL for months 7-12)
Number of subjects: 296
Study 15753847 — intervention group
Group type: COMPARATOR
Intervention: Lower C2 target range (800-1,000 ng/mL for months 4-6 and 600-800 ng/mL for months 7-12)
Number of subjects: 296
Study 15753847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both higher and lower C2 target ranges
Number of subjects: 296
Study 12762475 — intervention group
Group type: EXPERIMENTAL
Intervention: Photocolorimetric analysis
Number of subjects: 40
Study 12762475 — intervention group
Group type: COMPARATOR
Intervention: Conventional visual assessment
Number of subjects: 40
Study 10559813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of normal saline (NS)
Number of subjects: 34
Study 10559813 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary infusion of lactated Ringer's solution (LR)
Number of subjects: 34
Study 10559813 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary infusion of lactated Ringer's solution with 5% dextrose (D5LR)
Number of subjects: 34
Study 7904931 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective with no ISA)
Number of subjects: 21
Study 7904931 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-1-selective with no ISA)
Number of subjects: 21
Study 7904931 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (non-selective with ISA)
Number of subjects: 21
Study 7904931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3551618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine gel
Number of subjects: 80
Study 3551618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 4% solution
Number of subjects: 80
Study 3551618 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% solution
Number of subjects: 80
Study 3551618 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 80
Study 31647503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab, and docetaxel
Number of subjects: 329
Study 31647503 — intervention group
Group type: COMPARATOR
Intervention: Placebo, trastuzumab, and docetaxel
Number of subjects: 329
Study 31647503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 329
Study 31647503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 29446970 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0
Study 29446970 — intervention group
Group type: COMPARATOR
Intervention: Younger adults
Number of subjects: 0
Study 29446970 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 0
Study 26814889 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling (SCC)
Number of subjects: 0
Study 26814889 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no SCC)
Number of subjects: 0
Study 26814889 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendees of stop-smoking counseling
Number of subjects: 0
Study 26814889 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 0
Study 25533223 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Agatston score strata of 1 to 10
Number of subjects: 3559
Study 25533223 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Agatston score strata of 11 to 100
Number of subjects: 3559
Study 25533223 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Agatston score strata of 101 to 400
Number of subjects: 3559
Study 25533223 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Agatston score strata of >400
Number of subjects: 3559
Study 25533223 — intervention group
Group type: COMPARATOR
Intervention: Model with age, pack‐years, smoking status, and modified Agatston score strata
Number of subjects: 3559